首页> 美国卫生研究院文献>Diabetes Therapy >Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus

【2h】

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus

机译：胰高血糖素肽1受体激动剂在2型糖尿病患者中的胰高血糖素肽1受体激动剂的概括性概括

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version contains supplementary material available at 10.1007/s13300-021-01079-x.

机译：在线版本包含10.1007 / S13300-021-01079-X的补充材料。

著录项

期刊名称 Diabetes Therapy
作者
Xiaoling Cai; Linong Ji;
展开▼
作者单位

展开▼
年(卷),期 2021(12),7
年度 2021
页码 1861–1870
总页数 10
原文格式 PDF
正文语种
中图分类基础医学;
关键词

机译：心血管结果试验;中文;GLP-1受体激动剂;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide?1 Receptor Agonists in Chinese Patients with Type?2 Diabetes Mellitus [J] . Cai Xiaoling, Ji Linong Diabetes therapy . 2021,第7期

机译：胰高血糖素肽的心血管结果试验结果的概括性？1型糖尿病患者的胰腺炎患者1个受体激动剂
2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials [J] . Zelniker Thomas A., Wiviott Stephen D., Raz Itamar, Circulation: An Official Journal of the American Heart Association . 2019,第17期

机译：胰高血糖素样肽受体激动剂和钠 - 葡萄糖COT转折剂2抑制剂预防2型糖尿病系统审查和荟萃分析的糖尿病患者抑制剂预防糖尿病的重大不良心血管和肾外转移的影响
3. Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population [J] . Wittbrodt Eric T., Eudicone James M., Bell Kelly F., The American journal of managed care . 2018,第8Suppla期

机译：胰高血糖素类肽-1受体激动剂心血管结果试验的概括性招生标准给美国2型糖尿病人群
4. Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors [C] . Noushafarin Khajavi, Heike Biebermann, Matthias Tschop, ESPE Advanced Seminar in Developmental Endocrinology . 2017

机译：通过在多种代谢受体中起作用的合理设计肽激动剂治疗糖尿病和肥胖症
5. Pharmacodynamic effects of ghrelin agonist RM-131 in patients with type 1 and type 2 diabetes mellitus and prior documentation of delayed gastric emptying. [D] . Shin, Andrea S. 2013

机译：ghrelin激动剂RM-131在1型和2型糖尿病患者中的药效作用以及先前记录的胃排空延迟。
6. Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis [O] . Xiaowen Zhang, Fei Shao, Lin Zhu, 2018

机译：2型糖尿病中胰高血糖素样肽1受体激动剂的心血管和微血管预后：一项采用试验顺序分析的随机对照心血管预后试验的荟萃分析
7. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials [O] . Jing Qin, Li Song 2019

机译：胰高血糖素的肽-1（GLP-1）受体激动剂和患有2型糖尿病患者的心血管事件：双盲，随机，安慰剂对照临床试验的META分析

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus

摘要

著录项

相似文献

相关主题

期刊订阅